What BMI qualifies for Mounjaro in the UK?

Is a BMI of 30 the only number that matters for Mounjaro?

Not quite. The licensed eligibility for Mounjaro covers two distinct groups of adults. The first group needs a BMI of 30 or above with no additional conditions required. The second group qualifies at a lower BMI of 27 or above, provided they have at least one weight-related health condition alongside it.

Qualifying conditions in that second group include type 2 diabetes, high blood pressure (hypertension), dyslipidaemia (raised cholesterol or triglycerides), obstructive sleep apnoea, and cardiovascular disease. Prediabetes and osteoarthritis are also recognised under the broader weight-related condition definition in the Mounjaro SmPC. If you sit between 27 and 29.9 and have one of these conditions, you are within the licensed range, something many people don't realise when they first look into treatment.

It is also worth knowing that UK guidance, including NICE's appraisal of tirzepatide (TA1026), adjusts these thresholds downward by 2.5 kg/m² for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, reflecting differences in how weight-related health risks present at lower BMI values. So for those groups, the main threshold effectively becomes 27.5, and the lower threshold becomes 24.5 with a qualifying condition.

If you want to understand how BMI works in the context of Mounjaro eligibility before speaking to a prescriber, the NHS BMI calculator is a straightforward place to start.

What does the NHS require, and why is it so different?

If you are hoping to access Mounjaro through the NHS, the thresholds are substantially higher than the licensed minimum, and rollout is happening in phases. NICE recommended tirzepatide in December 2024 (TA1026), but with NHS commissioning conditions that go far beyond BMI.

The current NHS cohort requires a BMI of at least 40 plus four or more of five specific conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. A second cohort, activated in June 2026, covers BMI 35 to 39.9 with four or more of those same conditions. Future phases will broaden access further, moving to three qualifying conditions by around March 2027. Ethnic-background adjustments of 2.5 kg/m² apply throughout.

These phases reflect NHS capacity planning, not clinical evidence about who benefits. Many people who are medically suitable under the licence simply do not meet the NHS criteria yet, or face long waiting lists even when they do. Our page on how to qualify for Mounjaro sets out both the NHS and private routes side by side if you want the fuller comparison.

Private prescribing through a regulated pharmacy follows the licensed eligibility (the BMI thresholds set by the manufacturer and approved by the MHRA) rather than the NHS commissioning criteria. That is a meaningful distinction for anyone currently sitting in the gap.

Does meeting the BMI threshold mean a prescriber will approve Mounjaro?

Reaching the BMI threshold means you are eligible to be assessed, it does not guarantee a prescription. A GPhC-registered prescriber reviews your full clinical picture: your medical history, any existing medications, and whether there are any contraindications.

There are conditions where Mounjaro is not appropriate regardless of BMI. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2), a history of pancreatitis, or certain gastrointestinal conditions all require careful prescriber discussion. Mounjaro is not licensed for use in pregnancy, and it is not recommended for anyone who is breastfeeding or actively trying to conceive. It is not licensed for anyone under 18.

It is also worth acknowledging that if you have looked at your BMI and felt uncertain about what BMI you need for Mounjaro, that is entirely understandable. The numbers, thresholds and conditions can feel like a maze. The consultation process with a prescriber exists precisely to work through that clearly, with your actual health details in front of them rather than a general chart. You can read more about what the full qualification process involves on our qualification criteria page, and details of our clinical team are on the clinical team page.

What about cost, does BMI affect what you pay?

BMI does not directly change what Mounjaro costs, but it shapes which dose you start on and how quickly treatment progresses, and dose affects price. Treatment begins at 2.5mg (a tolerability dose, to let your system settle) and is titrated upward by the prescriber, typically in four-week steps, through 5mg, 7.5mg, 10mg, 12.5mg and up to 15mg.

For context on private pricing, our Mounjaro pricing page sets out what to expect from the market and what is included in a legitimate private prescription. At nume, one transparent price covers the consultation, prescription, treatment and free next-working-day delivery, no subscription, no hidden extras. If you want a broader look at your treatment options before deciding, the weight-loss treatment overview covers what is currently available.

Once you are ready to take the next step, you can find out more about whether you would qualify for Mounjaro before starting a free consultation, where our prescribers assess whether it is clinically right for you specifically. That assessment is done by a real clinician, reviewing your answers the same day.